Ligustrazine Injection for Chronic Pulmonary Heart Disease: A Systematic Review and Meta-Analysis
Author Information
Author(s): Jian-sheng Li, Hai-feng Wang, Yun-ping Bai, Su-yun Li, Xue-qing Yu, Ya Li
Primary Institution: The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
Hypothesis
This study aimed to evaluate the efficacy and safety of ligustrazine injection for chronic pulmonary heart disease (CPHD).
Conclusion
There is some evidence suggesting potential effectiveness of ligustrazine injection for CPHD, but the results are limited by methodological flaws.
Supporting Evidence
- 34 RCTs with low methodological quality were included.
- Compared to conventional medicine treatment alone, ligustrazine injection plus conventional treatment showed improvement in NYHA classification.
- Three studies reported adverse events, but no serious adverse effects were reported.
Takeaway
Ligustrazine injection might help people with a heart problem called chronic pulmonary heart disease, but the studies done so far weren't very good.
Methodology
The study included randomized controlled trials (RCTs) of ligustrazine injection for CPHD, analyzed using Review Manager 5.0 software.
Potential Biases
Potential publication bias exists as all trials were published in Chinese.
Limitations
The methodological quality of most included trials was poor, with no proper randomization or blinding.
Participant Demographics
Participants ranged from 37 to 85 years old, with a majority being male (54% to 89%).
Statistical Information
P-Value
0.22
Confidence Interval
95% CI 0.17 to 0.28
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website